<jats:title>Abstract</jats:title><jats:p>Three new indoloquinazolidine‐type alkaloids, 8,13‐dihydro‐2‐methoxyindolo[2′,3′: 3,4]pyrido[2,1‐<jats:italic>b</jats:italic>]quinazolin‐5(7<jats:italic>H</jats:italic>)‐one (<jats:bold>1</jats:bold>), 8,13‐dihydro‐2‐methoxy‐13‐methylindolo[2′,3′: 3,4]pyrido[2,1‐<jats:italic>b</jats:italic>]quinazolin‐5(7<jats:italic>H</jats:italic>)‐one (<jats:bold>2</jats:bold>), and 5,8,13,14‐tetrahydro‐2‐methoxy‐14‐methyl‐5‐oxo‐7<jats:italic>H</jats:italic>‐indolo[2′,3′: 3,4]pyrido[2,1‐<jats:italic>b</jats:italic>]quinazolim‐6‐iun chloride (<jats:bold>3</jats:bold>) were isolated from <jats:italic>Araliopsis tabouensis</jats:italic>, together with three known compounds. The structures of the new compounds were determined primarily from 1D‐ and 2D‐NMR analysis. The antimalarial activities of compounds <jats:bold>1</jats:bold>–<jats:bold>5</jats:bold> were evaluated against <jats:italic>Plasmodium falciparum</jats:italic> D6 and W2 clones. The <jats:italic>IC</jats:italic><jats:sub>50</jats:sub> values in antimalarial bioassay for compounds <jats:bold>2</jats:bold>–<jats:bold>5</jats:bold> varied from 1.8 to 4.7 μg/ml.